此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Temporal Interference Noninvasive Deep Brain Stimulation for Idiopathic Parkinson's Disease and Parkinsonian Syndromes: Effects and Target Exploration

2026年7月10日 更新者:Shengdi Chen、Ruijin Hospital

A Study on the Therapeutic Effects and Target Exploration of Temporal Interference-Based Noninvasive Deep Brain Stimulation in Patients With Idiopathic Parkinson's Disease and Parkinsonian Syndromes

This study aims to explore the therapeutic effects of noninvasive deep brain electrical stimulation using temporal interference principles (Temporal Interference Stimulation, TIS) on both motor and non-motor symptoms in patients with idiopathic Parkinson's disease and Parkinsonian syndromes, and to investigate strategies for optimal stimulation target selection. A prospective, single-center, double-blind, randomized, crossover design will be implemented. Participants will be recruited from outpatient and inpatient departments of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine. The primary hypothesis is that TIS will significantly improve motor symptoms in patients with Parkinson's disease and Parkinsonian syndromes. The primary outcome measure will be the change in the MDS-UPDRS Part III score from baseline to post-stimulation.

This study is expected to provide direct evidence supporting the clinical application and target selection strategies of noninvasive deep brain stimulation for the treatment of Parkinson's disease and Parkinsonian syndromes.

研究概览

研究类型

介入性

注册 (估计的)

100

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Shanghai、中国
        • Shanghai Jiao Tong University School of Medicine Affiliated Ruijin Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

  1. Aged 40 to 80 years, diagnosed with idiopathic Parkinson's disease or Parkinsonian syndromes according to the Movement Disorder Society (MDS) diagnostic criteria.
  2. Receiving stable doses of levodopa or other dopaminergic medications for at least 4 weeks prior to enrollment, with a documented response to levodopa; medication regimen must remain unchanged during the study.
  3. Hoehn and Yahr (H&Y) stage ≤ 3 in the "ON" medication state.
  4. Normal cognitive function, defined as a Mini-Mental State Examination (MMSE) score ≥ 24.
  5. Able to maintain and cooperate with Parkinson's disease symptom diaries.
  6. Signed written informed consent.

Exclusion Criteria:

  1. Presence of other neurological or psychiatric disorders that may interfere with study participation or outcomes.
  2. Previous treatment with deep brain stimulation (DBS) or other invasive brain stimulation therapies.
  3. Orthopedic or other medical conditions that could affect gait or balance.
  4. Contraindications to MRI, such as claustrophobia or other factors making MRI unsuitable.
  5. History of taking antipsychotic, antidepressant, or other medications that may affect dopamine levels.
  6. Contraindications to electrical stimulation, such as implanted cardiac pacemakers or a history of epilepsy.
  7. History of electroconvulsive therapy (ECT).
  8. Severe comorbidities, including cardiovascular disease, respiratory disease, or hepatic/renal dysfunction.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:交叉作业
  • 屏蔽:三倍

武器和干预

参与者组/臂
干预/治疗
实验性的:GPi TIS
Participants with PD or PDS receive TIS targeting the contralateral globus pallidus internus (GPi). Each group consists of 10 patients with PD and 10 patients with PDS.
Participants with PD or PDS receive TIS. Each session lasts 30 minutes for 3 consecutive days. The study uses a crossover design with AB sequence (Active → Sham). Active stimulation: current 1.5-4 mA (patient's maximum tolerated), carrier frequency 2000 Hz, frequency offset 130 Hz; Sham stimulation: current 1.5-4 mA, carrier frequency 2000 Hz, frequency offset 0 Hz.
Participants with PD or PDS receive TIS. Each session lasts 30 minutes for 3 consecutive days. The study uses a crossover design with BA sequence (Sham → Active). Sham stimulation: current 1.5-4 mA, carrier frequency 2000 Hz, frequency offset 0 Hz. Active stimulation: current 1.5-4 mA (patient's maximum tolerated), carrier frequency 2000 Hz, frequency offset 130 Hz;
实验性的:STN TIS
Participants with PD or PDS receive TIS targeting the contralateral subthalamic nucleus (STN). Each group consists of 10 patients with PD and 10 patients with Parkinsonian syndromes.
Participants with PD or PDS receive TIS. Each session lasts 30 minutes for 3 consecutive days. The study uses a crossover design with AB sequence (Active → Sham). Active stimulation: current 1.5-4 mA (patient's maximum tolerated), carrier frequency 2000 Hz, frequency offset 130 Hz; Sham stimulation: current 1.5-4 mA, carrier frequency 2000 Hz, frequency offset 0 Hz.
Participants with PD or PDS receive TIS. Each session lasts 30 minutes for 3 consecutive days. The study uses a crossover design with BA sequence (Sham → Active). Sham stimulation: current 1.5-4 mA, carrier frequency 2000 Hz, frequency offset 0 Hz. Active stimulation: current 1.5-4 mA (patient's maximum tolerated), carrier frequency 2000 Hz, frequency offset 130 Hz;
实验性的:Putamen TIS
Participants with PD or PDS receive TIS targeting the contralateral putamen. Each group consists of 10 patients with PD and 10 patients with Parkinsonian syndromes.
Participants with PD or PDS receive TIS. Each session lasts 30 minutes for 3 consecutive days. The study uses a crossover design with AB sequence (Active → Sham). Active stimulation: current 1.5-4 mA (patient's maximum tolerated), carrier frequency 2000 Hz, frequency offset 130 Hz; Sham stimulation: current 1.5-4 mA, carrier frequency 2000 Hz, frequency offset 0 Hz.
Participants with PD or PDS receive TIS. Each session lasts 30 minutes for 3 consecutive days. The study uses a crossover design with BA sequence (Sham → Active). Sham stimulation: current 1.5-4 mA, carrier frequency 2000 Hz, frequency offset 0 Hz. Active stimulation: current 1.5-4 mA (patient's maximum tolerated), carrier frequency 2000 Hz, frequency offset 130 Hz;
实验性的:LHA TIS
Participants with PD or PDS receive TIS targeting the contralateral lateral hypothalamic area (LHA). Each group consists of 10 patients with PD and 10 patients with Parkinsonian syndromes.
Participants with PD or PDS receive TIS. Each session lasts 30 minutes for 3 consecutive days. The study uses a crossover design with AB sequence (Active → Sham). Active stimulation: current 1.5-4 mA (patient's maximum tolerated), carrier frequency 2000 Hz, frequency offset 130 Hz; Sham stimulation: current 1.5-4 mA, carrier frequency 2000 Hz, frequency offset 0 Hz.
Participants with PD or PDS receive TIS. Each session lasts 30 minutes for 3 consecutive days. The study uses a crossover design with BA sequence (Sham → Active). Sham stimulation: current 1.5-4 mA, carrier frequency 2000 Hz, frequency offset 0 Hz. Active stimulation: current 1.5-4 mA (patient's maximum tolerated), carrier frequency 2000 Hz, frequency offset 130 Hz;
实验性的:Dentate TIS
Participants with PD or PDS receive TIS targeting the ipsilateral cerebellar dentate nucleus. Each group consists of 10 patients with PD and 10 patients with Parkinsonian syndromes.
Participants with PD or PDS receive TIS. Each session lasts 30 minutes for 3 consecutive days. The study uses a crossover design with AB sequence (Active → Sham). Active stimulation: current 1.5-4 mA (patient's maximum tolerated), carrier frequency 2000 Hz, frequency offset 130 Hz; Sham stimulation: current 1.5-4 mA, carrier frequency 2000 Hz, frequency offset 0 Hz.
Participants with PD or PDS receive TIS. Each session lasts 30 minutes for 3 consecutive days. The study uses a crossover design with BA sequence (Sham → Active). Sham stimulation: current 1.5-4 mA, carrier frequency 2000 Hz, frequency offset 0 Hz. Active stimulation: current 1.5-4 mA (patient's maximum tolerated), carrier frequency 2000 Hz, frequency offset 130 Hz;

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Efficacy of temporal interference stimulation (TIS) on motor symptoms in patients with idiopathic Parkinson's disease and Parkinsonian syndromes
大体时间:Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
The MDS-UPDRS Part III is a rater-administered motor examination used to evaluate the severity of motor impairment in patients with idiopathic Parkinson's disease and Parkinsonian syndromes. The total score ranges from 0 to 132, with lower scores indicating less severe motor symptoms. Changes from baseline after real or sham stimulation will be analyzed and compared between groups.
Baseline, 3 days after sham stimulation, and 3 days after active stimulation.

次要结果测量

结果测量
措施说明
大体时间
Secondary motor outcome
大体时间:Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
The UMSARS is a rater-administered scale used to assess disease severity in patients with Parkinsonian syndromes, particularly multiple system atrophy. The total score ranges from 0 to 104, with a higher score indicating greater disease severity. The change in UMSARS score from baseline to after stimulation will be compared between the real and sham stimulation groups.
Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
Secondary motor outcome
大体时间:Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
The Freezing of Gait Questionnaire is used to assess the severity and frequency of freezing of gait in patients with idiopathic Parkinson's disease and Parkinsonian syndromes. The total score ranges from 0 to 24, with a higher score indicating more severe freezing of gait. The change in FOGQ score from baseline to after stimulation will be compared between the real and sham stimulation groups.
Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
Secondary motor outcome
大体时间:Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
The Berg Balance Scale is a rater-administered scale used to assess balance function and fall risk. The total score ranges from 0 to 56, with a higher score indicating better balance function. The change in Berg Balance Scale score from baseline to after stimulation will be compared between the real and sham stimulation groups.
Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
Efficacy of TIS on non-motor symptoms in patients with idiopathic Parkinson's disease and Parkinsonian syndromes
大体时间:Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
The Hamilton Anxiety Rating Scale-14(HAMA-14)is a rater-administered scale used to assess the severity of anxiety symptoms. The total score ranges from 0 to 56, with a higher score indicating more severe anxiety. The change in HAMA-14 score from baseline to after stimulation will be compared between the real and sham stimulation groups.
Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
Efficacy of TIS on non-motor symptoms in patients with idiopathic Parkinson's disease and Parkinsonian syndromes
大体时间:Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
The Hamilton Depression Rating Scale-17(HAMD-17)is a rater-administered scale used to assess the severity of depressive symptoms. The total score ranges from 0 to 52, with a higher score indicating more severe depression. The change in HAMD-17 score from baseline to after stimulation will be compared between the real and sham stimulation groups.
Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
Efficacy of TIS on non-motor symptoms in patients with idiopathic Parkinson's disease and Parkinsonian syndromes
大体时间:Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
The Mini-Mental State Examination(MMSE)is a brief cognitive screening scale used to assess global cognitive function. The total score ranges from 0 to 30, with a higher score indicating better cognitive function. The change in MMSE score from baseline to after stimulation will be compared between the real and sham stimulation groups.
Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
Efficacy of TIS on non-motor symptoms in patients with idiopathic Parkinson's disease and Parkinsonian syndromes
大体时间:Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
The Montreal Cognitive Assessment(MoCA)is a brief cognitive screening scale used to assess global cognitive function, particularly mild cognitive impairment. The total score ranges from 0 to 30, with a higher score indicating better cognitive function. The change in MoCA score from baseline to after stimulation will be compared between the real and sham stimulation groups.
Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
Efficacy of TIS on non-motor symptoms in patients with idiopathic Parkinson's disease and Parkinsonian syndromes
大体时间:Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
The Non-Motor Symptoms Scale(NMSS)is a rater-administered scale used to assess the severity and frequency of non-motor symptoms in patients with Parkinson's disease and Parkinsonian syndromes. The total score ranges from 0 to 360, with a higher score indicating a greater non-motor symptom burden. The change in NMSS score from baseline to after stimulation will be compared between the real and sham stimulation groups.
Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
Efficacy of TIS on non-motor symptoms in patients with idiopathic Parkinson's disease and Parkinsonian syndromes
大体时间:Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
The Scales for Outcomes in Parkinson's Disease-Autonomic Dysfunction(SCOPA-AUT)is a patient-reported scale used to assess autonomic symptoms in patients with Parkinson's disease and Parkinsonian syndromes. The total score ranges from 0 to 69, with a higher score indicating more severe autonomic dysfunction. The change in SCOPA-AUT score from baseline to after stimulation will be compared between the real and sham stimulation groups.
Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
Efficacy of TIS on quality of life in patients with idiopathic Parkinson's disease and Parkinsonian syndromes
大体时间:Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
The Parkinson's Disease Questionnaire-39 Summary Index(PDQ-39 SI)is a patient-reported scale used to assess health-related quality of life in patients with Parkinson's disease and Parkinsonian syndromes. The total score ranges from 0 to 100, with a higher score indicating poorer quality of life. The change in PDQ-39 SI score from baseline to after stimulation will be compared between the real and sham stimulation groups.
Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
Efficacy of TIS on quality of life in patients with idiopathic Parkinson's disease and Parkinsonian syndromes
大体时间:Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
The MDS-UPDRS Part I is used to assess non-motor experiences of daily living in patients with idiopathic Parkinson's disease and Parkinsonian syndromes. The total score ranges from 0 to 52, with a higher score indicating more severe non-motor symptom burden. The change in MDS-UPDRS Part I score from baseline to after stimulation will be compared between the real and sham stimulation groups.
Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
Efficacy of TIS on quality of life in patients with idiopathic Parkinson's disease and Parkinsonian syndromes
大体时间:Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
The MDS-UPDRS Part II is used to assess motor experiences of daily living in patients with idiopathic Parkinson's disease and Parkinsonian syndromes. The total score ranges from 0 to 52, with a higher score indicating greater motor-related impairment in daily living. The change in MDS-UPDRS Part II score from baseline to after stimulation will be compared between the real and sham stimulation groups.
Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
Potential mechanisms underlying the therapeutic effects of TIS in patients with idiopathic Parkinson's disease and Parkinsonian syndromes
大体时间:Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
Changes in resting-state EEG β-band oscillation power before and after stimulation
Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
Potential mechanisms underlying the therapeutic effects of TIS in patients with idiopathic Parkinson's disease and Parkinsonian syndromes
大体时间:Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
Changes in whole-brain resting-state fMRI functional connectivity strength, with exploratory analyses focusing on the sensorimotor and basal ganglia networks, before and after stimulation
Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)
大体时间:From baseline through study completion (up to 3 weeks)
The number and severity of all AEs and SAEs will be collected and monitored throughout the study to evaluate the safety and tolerability of the intervention.
From baseline through study completion (up to 3 weeks)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年7月3日

初级完成 (估计的)

2026年9月30日

研究完成 (估计的)

2026年9月30日

研究注册日期

首次提交

2025年12月8日

首先提交符合 QC 标准的

2026年7月10日

首次发布 (实际的)

2026年7月13日

研究记录更新

最后更新发布 (实际的)

2026年7月13日

上次提交的符合 QC 标准的更新

2026年7月10日

最后验证

2026年7月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅